Xiaotian Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaotian Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- C. Su
Graduate School of Biomedical Science, Rutgers University, Piscataway, USA
1 shared publication - Feifei Chen
Institute of Oncology, Xuzhou Medical University, Xuzhou, China
1 shared publication - Jian Wang
Department of Plastic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication - Lingqiong Meng
Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, AZ 85724, USA
1 shared publication - Mengqi Leng
Xuzhou Medical University, Xuzhou, China
1 shared publication - Peisheng Jin
Department of Plastic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication
Latest Publications
- 17 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1148-1160.e15
N6-Methyladenosine Modification of lncCCKAR-5 Regulates Autophagy in Human Umbilical Cord Mesenchymal Stem Cells by Destabilizing LMNA and Inhibits Diabetic Wound Healing
- 17 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1148-1160.e15
N6-Methyladenosine Modification of lncCCKAR-5 Regulates Autophagy in Human Umbilical Cord Mesenchymal Stem Cells by Destabilizing LMNA and Inhibits Diabetic Wound Healing
- 19 July 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (2) , 301-307
Total and free vitamin D metabolites in patients with primary hyperparathyroidism
Purpose To evaluate total and free vitamin D metabolites and hormone-to-prohormone [1,25(OH)2D/25(OH)D] “activation ratio” in PHPT patients with low or insufficient vitamin D status. Methods Thirty female patients with primary hyperparathyroidism (PHPT) and 30 age and body mass index (BMI) matched healthy controls were enrolled. Serum levels of calcium, intact parathyroid hormone (iPTH), vitamin D binding protein (DBP), albumin, total 25(OH)D and 1,25(OH)2D were measured. The activation ratio of vitamin D was calculated as total 1,25(OH)2D/25(OH)D. Calculated serum-free 25(OH)D and 1,25(OH)2D levels were also reported. Results Compared to the control subject, patients with PHPT had a lower total 25(OH)D and DBP levels (p < 0.001). The serum concentration of free 25(OH)D and total 1,25(OH)2D were similar between the two groups; but free 1,25(OH)2D levels were about 26% higher in the PHPT patients compared to controls (p < 0.001). PHPT patients had a significantly higher activation ratio (p < 0.01), although their total 25(OH)D were lower than controls. The free (but not total) 1,25(OH)2D level was inversely correlated with DBP (p < 0.01). Both free 1,25(OH)2D levels and activation ratio were positively correlated with iPTH and calcium levels (p < 0.01). The activation ratio was highly correlated with levels of total vitamin D stores and free vitamin D metabolites (p < 0.001). Conclusion Patients with PHPT had significantly higher free 1,25(OH)2D levels and activation ratio compared to control subjects. We suggest that levels of free vitamin D metabolites and vitamin D activation ratio may provide additional values for the diagnosis and therapeutic choices in these patient populations with compromised vitamin D status.
- 19 July 2021
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 45 (2) , 301-307
Total and free vitamin D metabolites in patients with primary hyperparathyroidism
Purpose To evaluate total and free vitamin D metabolites and hormone-to-prohormone [1,25(OH)2D/25(OH)D] “activation ratio” in PHPT patients with low or insufficient vitamin D status. Methods Thirty female patients with primary hyperparathyroidism (PHPT) and 30 age and body mass index (BMI) matched healthy controls were enrolled. Serum levels of calcium, intact parathyroid hormone (iPTH), vitamin D binding protein (DBP), albumin, total 25(OH)D and 1,25(OH)2D were measured. The activation ratio of vitamin D was calculated as total 1,25(OH)2D/25(OH)D. Calculated serum-free 25(OH)D and 1,25(OH)2D levels were also reported. Results Compared to the control subject, patients with PHPT had a lower total 25(OH)D and DBP levels (p < 0.001). The serum concentration of free 25(OH)D and total 1,25(OH)2D were similar between the two groups; but free 1,25(OH)2D levels were about 26% higher in the PHPT patients compared to controls (p < 0.001). PHPT patients had a significantly higher activation ratio (p < 0.01), although their total 25(OH)D were lower than controls. The free (but not total) 1,25(OH)2D level was inversely correlated with DBP (p < 0.01). Both free 1,25(OH)2D levels and activation ratio were positively correlated with iPTH and calcium levels (p < 0.01). The activation ratio was highly correlated with levels of total vitamin D stores and free vitamin D metabolites (p < 0.001). Conclusion Patients with PHPT had significantly higher free 1,25(OH)2D levels and activation ratio compared to control subjects. We suggest that levels of free vitamin D metabolites and vitamin D activation ratio may provide additional values for the diagnosis and therapeutic choices in these patient populations with compromised vitamin D status.